# US 2026/0098038 A1 · Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098038 A1
- Document ID: US20260098038A1
- Status: Published application
- Kind: A1
- Application number: 19/418,159
- Filed: 2025-12-12
- Published: 2026-04-09
- Earliest claimed: 2019-11-15
- Assignees: Yuhan Corporation; The Green Cross Corporation
- Applicants: Yuhan Corporation; Green Cross Corporation
- Inventors: Dong-Hoon KIM; Jae-Eun JOO; Eui-Chul LEE; Tae-Dong HAN; Seung-Yub SHIN; Sool-Ki KWON; Ji-Hye KIM
- Web page: https://patentgrep.com/patent/US20260098038A1

## CPC

- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 471/08: Bridged systems
- A61P 25/16: Anti-Parkinson drugs
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, where the. The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

## Claims

### Claim 1

A compound of Formula 5:
wherein,
Y and Z are, independently of each other, —CR1R2—; —NR3—; —O—; or —S—,
R1 and R2 are, independently of each other, hydrogen; halogen; C1-C6 alkyl; C1-C6 alkyl having a nitrogen, oxygen, or sulfur atom; C3-C10 cycloalkyl; 3- to 12-membered heterocyclic; or C1-C6 alkoxy; or R1 and R2 form C3-C10 cycloalkyl together with the carbon atom to which they are attached,
R3 is hydrogen; C1-C6 alkyl; C1-C6 alkyl having a nitrogen, oxygen, or sulfur atom; C3-C10 cycloalkyl; 3- to 12-membered heterocyclic; or C1-C6 alkoxy,
X is hydrogen; halogen; C1-C6 alkyl; C1-C6 alkyl substituted with 1 to 3 halogens; C1-C6 alkyl having a nitrogen, oxygen, or sulfur atom; C1-C6 alkoxy; or C1-C6 alkoxy substituted with 1 to 3 halogens.

### Claim 2 (depends on 1)

The compound as claimed in claim 1, wherein
Y and Z are, independently of each other, —O— or —CR1R2—, and
R1 and R2 are, independently of each other, hydrogen or C1-C6 alkyl; or R1 and R2 form C3-C10 cycloalkyl together with the carbon atom to which they are attached.

### Claim 3 (depends on 1)

The compound as claimed in claim 1, wherein Y is —O—; and Z is —CR1R2—.

### Claim 4 (depends on 1)

The compound as claimed in claim 1, wherein X is hydrogen, halogen, or C1-C6 alkoxy.

### Claim 5 (depends on 1)

The compound as claimed in claim 1, wherein the compound is (S)-quinuclidin-3-yl (5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate.

### Claim 6

A process for preparing a compound of Formula 1a or pharmaceutically acceptable salt thereof, the process of which comprises reacting a compound of Formula 5 with a A-W-boronic acid substituted with X1, X2, X3, or X4 to obtain a compound of Formula 1a; and optionally converting the compound of Formula 1a to a pharmaceutically acceptable salt thereof:
wherein,
Y and Z are, independently of each other, —CR1R2—; —NR3—; —O—; or —S—,
R1 and R2 are, independently of each other, hydrogen; halogen; C1-C6 alkyl; C1-C6 alkyl having a nitrogen, oxygen, or sulfur atom; C3-C10 cycloalkyl; 3- to 12-membered heterocyclic; or C1-C6 alkoxy; or R1 and R2 form C3-C10 cycloalkyl together with the carbon atom to which they are attached,
R3 is hydrogen; C1-C6 alkyl; C1-C6 alkyl having a nitrogen, oxygen, or sulfur atom; C3-C10 cycloalkyl; 3- to 12-membered heterocyclic; or C1-C6 alkoxy,
X is hydrogen; halogen; C1-C6 alkyl; C1-C6 alkyl substituted with 1 to 3 halogens; C1-C6 alkyl having a nitrogen, oxygen, or sulfur atom; C1-C6 alkoxy; or C1-C6 alkoxy substituted with 1 to 3 halogens,
W is a bond, —CH2—, —O—, —NH—, —CH2CH2—, —CH═CH—, or —C≡C—,
A ring is 6- to 12-membered aryl; 5- to 12-membered heteroaryl; C3-C10 cycloalkyl; or 3- to 12-membered heterocyclic, and
X1, X2, X3, and X4 are, independently of each other, hydrogen; cyano; halogen; C1-C6 alkyl; C1-C6 alkoxy-C1-C6 alkyl; C1-C6 alkyl substituted with 1 to 3 halogens; C3-C10 cycloalkyl; 3- to 12-membered heterocyclic; C1-C6 alkoxy; C1-C6 alkoxy substituted with 1 to 3 halogens; C1-C6 alkoxy-C1-C6 alkoxy; morpholinyl-C1-C6 alkoxy; mono- or di-C1-C6 alkylamino-C1-C6 alkoxy; C3-C10 cycloalkyl-C1-C6 alkoxy; C1-C6 alkylthio; amino; mono- or di-C1-C6 alkylamino; C1-C6 alkylcarbonyl; hydroxy; or nitro.

### Claim 7 (depends on 6)

The process as claimed in claim 6, wherein the reacting a compound of Formula 5 with a A-W-boronic acid substituted with X1, X2, X3, or X4 is carried out using a palladium catalyst.

### Claim 8 (depends on 6)

The process as claimed in claim 6, wherein the reacting a compound of Formula 5 with a A-W-boronic acid substituted with X1, X2, X3, or X4 is carried out in the presence of an inorganic base.

### Claim 9 (depends on 6)

The process as claimed in claim 6, wherein the compound of Formula 5 is obtained by coupling a compound of Formula 3 with quinuclidinol:
wherein, X, Y, and Z are the same as defined in the claim 6.

### Claim 10 (depends on 9)

The process as claimed in claim 9, wherein the coupling is carried out through a condensation reaction including the removal of ethanol.

### Claim 11 (depends on 6, 9)

The process as claimed in claim 9, wherein the compound of Formula 3 is obtained by reacting a compound of Formula 2 or salt thereof with ethyl chloroformate:
wherein, X, Y, and Z are the same as defined in the claim 6.

### Claim 12 (depends on 11)

The process as claimed in claim 11, wherein the reacting a compound of Formula 2 or salt thereof with ethyl chloroformate is carried out in the presence of a base.

### Claim 13 (depends on 6)

The process as claimed in claim 6, wherein the compound of Formula 5 is obtained by reacting a compound of Formula 7 with a compound of Formula 2:
wherein, X, Y, and Z are the same as defined in the claim 6.

### Claim 14 (depends on 13)

The process as claimed in claim 13, wherein the reacting a compound of Formula 7 with a compound of Formula 2 is carried out in the presence of a base.

### Claim 15 (depends on 13)

The process as claimed in claim 13, wherein the compound of Formula 7 is obtained by reacting quinuclidinol with bis(4-nitrophenyl) carbonate.

### Claim 16 (depends on 13)

The process as claimed in claim 13, wherein the compound of Formula 7 is obtained by reacting quinuclidinol with 4-nitrophenyl chloroformate.
